Schrödinger receives $57M from Lilly's acquisition of co-founded Ajax Therapeutics

Schrodinger, Inc.

Received ~$57M cash from Eli Lilly's acquisition of Ajax Therapeutics, a company co-founded by Schrödinger.
Eligible for additional cash payments upon achievement of specified clinical and regulatory milestones by Ajax.
Acquisition completed June 29, 2026; Ajax is a biotech company co-founded by Schrödinger.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.